1561 related articles for article (PubMed ID: 18354866)
1. The federal preemption debate in pharmaceutical labeling product liability actions.
Gross JM; Curry JA
Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
[No Abstract] [Full Text] [Related]
2. The case for preemption of prescription drug failure-to-warn claims.
Kim CH
Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
[No Abstract] [Full Text] [Related]
3. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
Dorfman HL; Quinn VM; Brophy EA
Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
[No Abstract] [Full Text] [Related]
4. The Supreme Court, preemption, and malpractice liability.
Kesselheim AS; Studdert DM
N Engl J Med; 2009 Feb; 360(6):559-61. PubMed ID: 19196672
[No Abstract] [Full Text] [Related]
5. Should preemption apply in a pharmaceutical context? An analysis of the preemption debate and what regulatory compliance statutes contribute to the discussion.
Surprenant JA
Fordham Law Rev; 2008 Oct; 77(1):327-63. PubMed ID: 18982554
[TBL] [Abstract][Full Text] [Related]
6. Good law from tragic facts--Congress, the FDA, and preemption.
Annas GJ
N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383
[No Abstract] [Full Text] [Related]
7. A defense of the learned intermediary doctrine.
Goetz RB; Growdon KR
Food Drug Law J; 2008; 63(2):421-38. PubMed ID: 18561470
[No Abstract] [Full Text] [Related]
8. "Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions.
Chodock R; Yolkut D; Connolly DR
Tort Trial Insur Pract Law J; 2005; 40(3):997-1017. PubMed ID: 16100814
[TBL] [Abstract][Full Text] [Related]
9. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health.
Gostin LO
JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642
[No Abstract] [Full Text] [Related]
10. Preemption and malpractice liability.
Hauser RG
N Engl J Med; 2009 May; 360(21):2257-8; author reply 2258. PubMed ID: 19458378
[No Abstract] [Full Text] [Related]
11. A state of extinction: does Food and Drug Administration approval of a prescription drug label extinguish state claims for inadequate warning?
O'Reilly JT
Food Drug Law J; 2003; 58(2):287-97. PubMed ID: 12866560
[No Abstract] [Full Text] [Related]
12. Bad medicine: prescription drugs, preemption, and the potential for a no-fault fix.
Smirniotopoulos A
Rev Law Soc Change; 2012; 35(4):793-862. PubMed ID: 22363960
[TBL] [Abstract][Full Text] [Related]
13. Pros and cons of off-label promotion investigations and prosecutions.
Loucks MK
Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
[No Abstract] [Full Text] [Related]
14. Tort claims and federal regulation of medical devices vs pharmaceuticals.
Green M
JAMA; 2009 Sep; 302(11):1169; author reply 1169-70. PubMed ID: 19755694
[No Abstract] [Full Text] [Related]
15. The learned intermediary doctrine: past, present and future.
Alsobrook HB
Leg Med; 1994; ():269-80. PubMed ID: 7830482
[No Abstract] [Full Text] [Related]
16. Drug review "behind the curtain": a response to Professor Struve.
O'Reilly JT
Cornell Law Rev; 2008 Jul; 93(5):1075-90. PubMed ID: 18618971
[No Abstract] [Full Text] [Related]
17. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
Berry MD
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449
[No Abstract] [Full Text] [Related]
18. Consumer-directed advertising of contraceptive drugs: the FDA, Depo-Provera, and product liability.
Green W
Food Drug Law J; 1995; 50(4):553-67. PubMed ID: 10343019
[No Abstract] [Full Text] [Related]
19. Injecting Safety into Supplements - Modernizing the Dietary Supplement Law.
Cohen PA; Bass S
N Engl J Med; 2019 Dec; 381(25):2387-2389. PubMed ID: 31851798
[No Abstract] [Full Text] [Related]
20. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
O'Reilly JT
Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
[No Abstract] [Full Text] [Related]
[Next] [New Search]
